Evidence map›Paper›PMID 19554091›Full record

ReviewVascular health and risk management2009

Treatment of pediatric pulmonary hypertension.

Amy Hawkins, Robert Tulloh

Abstract readReview
In one paragraph

Review in Vascular health and risk management, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Sildenafil citrate, bronchopulmonary dysplasia and disordered pulmonary gas exchange: any benefits?Journal of perinatology : official journal of the California Perinatal Association · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Amy HawkinsDepartment of Congenital Heart Disease, Bristol Royal Hospital for Children, Bristol BS2 8BJ, UK.
Robert Tulloh

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary hypertension was once thought to be a rare condition and only managed in specialized centers. Now however, with the advent of echocardiography, it is found in many clinical scenarios, in the neonate with chronic lung disease, in the acute setting in the intensive care unit, in connective tissue disease and in cardiology pre- and postoperatively. We have a better understanding of the pathological process and have a range of medication which is starting to be able to palliate this previously fatal condition. This review describes the areas that are known in this condition and those that are less familiar. The basic physiology behind pulmonary hypertension and pulmonary vascular disease is explained. The histopathologic process and the various diagnostic tools are described and are followed by the current and future therapy at our disposal.

Indexed as

AlgorithmsChildEchocardiographyEndothelin Receptor AntagonistsExtracorporeal Membrane OxygenationHumansHypertension, PulmonaryNitric OxidePhosphodiesterase InhibitorsPractice Guidelines as TopicProstaglandins IPulmonary ArteryEndothelin Receptor AntagonistsNitric OxidePhosphodiesterase InhibitorsProstaglandins Icongenital heart diseasepulmonary hypertensionpulmonary vascular resistancepulmonary vasodilators

Identifiers

PMID19554091
PMCPMC2697585

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.